Five Synexus Sites Randomise More Than 1300 Patients in Three Weeks

MANCHESTER, England--(BUSINESS WIRE)--Synexus® recently randomised more than 1300 patients in a vaccine study at five sites across Europe over a three week period, as part of a global programme.